Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-05-02
2011-12-27
Angell, Jon E (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A
Reexamination Certificate
active
08084600
ABSTRACT:
Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.
REFERENCES:
patent: 5670633 (1997-09-01), Cook et al.
patent: 5898031 (1999-04-01), Crooke et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 6005087 (1999-12-01), Cook et al.
patent: 6033909 (2000-03-01), Uhlmann et al.
patent: 6107094 (2000-08-01), Crooke et al.
patent: 6211349 (2001-04-01), Dale et al.
patent: 6476205 (2002-11-01), Buhr et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6531584 (2003-03-01), Cook et al.
patent: 6815432 (2004-11-01), Wheeler et al.
patent: 6858225 (2005-02-01), Semple et al.
patent: 7056704 (2006-06-01), Tuschl et al.
patent: 7078196 (2006-07-01), Tuschl et al.
patent: 7138517 (2006-11-01), Cook et al.
patent: 7432249 (2008-10-01), Crooke et al.
patent: 7432250 (2008-10-01), Crooke et al.
patent: 7629321 (2009-12-01), Crooke et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0148507 (2003-08-01), Fosnaugh et al.
patent: 2003/0175950 (2003-09-01), McSwiggen
patent: 2003/0190635 (2003-10-01), McSwiggen
patent: 2004/0019001 (2004-01-01), McSwiggen
patent: 2004/0152117 (2004-08-01), Giordano et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0107325 (2005-05-01), Manoharan et al.
patent: 2005/0233329 (2005-10-01), McSwiggen et al.
patent: 2005/0261212 (2005-11-01), McSwiggen
patent: 2006/0063731 (2006-03-01), Lewis et al.
patent: 2007/0004667 (2007-01-01), McSwiggen et al.
patent: 2007/0032441 (2007-02-01), McSwiggen et al.
patent: 2009/0215880 (2009-08-01), Li et al.
patent: 2009/0247606 (2009-10-01), McSwiggen et al.
patent: 2009/0281164 (2009-11-01), McSwiggen et al.
patent: 2002 326410 (2003-02-01), None
patent: 03/216324 (2003-09-01), None
patent: 04/266311 (2005-03-01), None
patent: 100 80 167 (2008-03-01), None
patent: 100 66 235 (2008-04-01), None
patent: 0 552 766 (2002-05-01), None
patent: 1 144 623 (2002-08-01), None
patent: 1 229 134 (2002-08-01), None
patent: 1 389 637 (2004-02-01), None
patent: 0 928 290 (2005-03-01), None
patent: 1 214 945 (2005-06-01), None
patent: 1 230 375 (2005-07-01), None
patent: 1 627 061 (2006-02-01), None
patent: 1 352 061 (2006-05-01), None
patent: 1 407 044 (2007-09-01), None
patent: 1 550 719 (2008-12-01), None
patent: 1 309 726 (2009-12-01), None
patent: 4095895 (2008-06-01), None
patent: WO 00/44914 (2000-08-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 02/096927 (2002-12-01), None
patent: WO 03/010180 (2003-02-01), None
patent: WO 03/066649 (2003-08-01), None
patent: WO 03/070895 (2003-08-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 2004/015107 (2004-02-01), None
patent: WO 2004/090105 (2004-10-01), None
patent: WO 2004/092383 (2004-10-01), None
patent: 2005/019453 (2005-03-01), None
patent: WO 2005021749 (2005-03-01), None
patent: 2005/115481 (2005-12-01), None
patent: WO 2007/128477 (2007-11-01), None
Shen J et al: “Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1” Gene Therapy, Macmillan Press Ltd., Basingstoke, GB, Feb. 2006; 13(3) :225-234.
Kim B et al: “Inhibition of Ocular Angiogenesis by siRNA Targeting Vascular Endothelial Growth Factor Pathway Genes Therapeutic Strategy for Herpetic Stromal Keratitis” Am. J. Pathol. Dec. 2004; 165(6) :2177-2185.
Al-Anouti et al.; “Comparative Analysis of Antisense RNA, Double-Stranded RNA, and Delta Ribozyme-Mediated Gene Regulation in Toxoplasma gondii”; Antisense and Nucleic Acid Drug Development; 12:275-281 (2002).
Bass; “The short answer”; Nature—News and Views, RNA Interference; 411:428-429 (2001).
Beigelman et al.; “Chemical Modification of Hammerhead Ribozymes”; The Journal of Biological Chemistry; 270(43):25702-25708 (1995).
Braasch et al.; “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene”; Biochemistry—Current Topics; 41(14):4503-4510 (2002).
Braasch et al.; “RNA Interference in Mammalian Cells by Chemically-Modified RNA”; Biochemistry; 42:7967-7975 (2003).
Bramsen et al.; “A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity”; Nucleic Acids Research; 37(9):2867-2881 (2009).
Bramsen et al.; “A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity [Supplemental Figures]”; Nucleic Acids Research; 37(9):2867-2881 (2009).
Chiu et al; “Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAi in Living Cells”; Chemistry & Biology; 11:1165-1175 (2004).
Chiu et al.; “siRNA function in RNAi: A chemical modification analysis”; RNA; 9:1034-1048 (2003).
Corey; “Chemical modification: the key to clinical application of RNA interference?”; The Journal of Clinical Investigation—Review Series; 117(12):3615-3622 (2007).
Crooke et al.; “Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates”; The Journal of Pharmacology and Experimental Therapeutics; 292(1):140-149 (2000).
Deleavey et al.; “Chemical Modification of siRNA”; Current Protocols in Nucleic Acid Chemistry [Published by John Wiley & Sons, Inc.]; 39:16.3.1-16.3.22 (2009).
Dorsett et al.; “siRNAs: Applications in Functional Genomics and Potential As Therapeutics”; Nature Reviews—Drug Discovery; 3:318-329 (2004).
Elbashir et al.; “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”; Nature; 411:494-498 (2001).
Hadwiger et al.; “Chemical modifications to achieve increased stability and sensitive detection of siRNA”; RNA Interference Technology—From Basic Science to Drug Development, Edited by Krishnarao Appasani, Published by Cambridge University Press; 14:194-206 (2005).
Harborth et al.; “Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing”; Antisense and Nucleic Acid Drug Development; 13:83-105 (2003).
Hasan et al.; “VEGF antagonists”; Expert Opin. Biol. Ther.—Review; 1(4):703-718 (2001).
Kawasaki et al.; “World of small RNAs: from ribozymes to siRNA and miRNA”; Differentiation—Review; 72:58-64 (2004).
Kennerdell et al.; “Heritable gene silencing inDrosophilausing double-stranded RNA”; Nature Biotechnology; 17:896-898 (2000).
Khan et al.; “Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes: In Vitro and In Vivo Studies”; Journal of Drug Targeting; 12(6):393-404 (2004).
Kim et al; “Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer”; Journal of Controlled Release; 129:107-116 (2008).
Kraynack et al.; “Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity”; RNA; 12:163-176 (2006).
Lipardi et al.; “RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs”; Cell; 107:297-307 (2001).
Miyagishi et al.; “Comparison of the Suppressive Effects of Antisense Oligonucleotides and siRNAs Directed Against the Same Targets in Mammalian Cells”; Antisense and Nucleic Acid Drug Development; 13:1-7 (2003).
Parrish et al.; “Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference”; Molecular Cell; 6:1077-1087 (2000).
Prakash et al.; “Positional Effect of Chemical Modifications on Short
Billy Eric
Hunziker Juerg
Natt Francois Jean-Charles
Schnell Christian Rene
Angell Jon E
Novartis AG
Wu Frank
LandOfFree
Short interfering ribonucleic acid (siRNA) with improved... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Short interfering ribonucleic acid (siRNA) with improved..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Short interfering ribonucleic acid (siRNA) with improved... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315134